Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
fluzoparib + abiraterone acetate + prednisone
- Development stage
- Unknown
- Lead developer
- Hengrui Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
This combination therapy consists of three agents: **fluzoparib**, **abiraterone acetate**, and **prednisone**. Fluzoparib is an oral PARP (poly ADP-ribose polymerase) inhibitor that interferes with DNA repair in cancer cells, particularly those with deficient homologous recombination, leading to increased cell death. Abiraterone acetate is a prodrug of abiraterone, which inhibits the enzyme CYP17A1 and blocks androgen biosynthesis—a key driver in prostate cancer progression. Prednisone is a corticosteroid used in this combination to mitigate the mineralocorticoid-related side effects associated with abiraterone, as well as to provide anti-inflammatory and possibly modest antitumor effects. This combination is being investigated as an induction regimen in prostate cancer, specifically metastatic castration-resistant prostate cancer (mCRPC)[5].
- Brand names
- Zytiga
- Other names
- CB7630CB-7630CB 7630JNJ21208JNJ-21208JNJ 21208
02
Targets
CYP17A1 (Steroid 17-alpha-hydroxylase/C17,20 lyase)PARP (PARP family)GR (Glucocorticoid receptor)
Beyond the preview
Go deeper on fluzoparib + abiraterone acetate + prednisone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on fluzoparib + abiraterone acetate + prednisone.